Activity Description
Non-small cell lung carcinoma (NSCLC) has increased in complexity due to identification of tumor subtypes and corresponding targeted therapies. This 30-minute, CME activity will feature Dr Ross Camidge and Dr Mark Socinski as they share insights into the selection of precision therapy for NSCLC based on tumor biomarkers and driver mutations, and strategies to proactively address treatment-related adverse events.
Educational Objectives:
Upon completion of this educational activity, learners should be better able to:
- IMPLEMENT molecular testing for patients with non-small cell lung carcinoma (NSCLC) based on expert consensus guidelines, including use of broad molecular profiling platforms
- DEVISE treatment plans for patients with NSCLC in whom driver mutations are detected, emphasizing use of first-line targeted therapies and strategies to approach patients progressing on targeted therapies
- MONITOR and MANAGE adverse effects that develop during targeted therapy, in order to minimize toxicities, enhance patient health-related quality of life (HQoL) and ensure continuation of beneficial therapies
Accreditor Disclosure of Conflicts of Interest Policy
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
Faculty Info:
D. Ross Camidge, MD, PhD
Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, CO
Faculty Disclosures:
Consultant/Advisory Board: AstraZeneca plc; Daiichi Sankyo Company, Limited; Elevation Pharmaceuticals Inc; Amgen; Anchiarno; Apollomics; Bio-Thera; Bristol Myers Squibb Company; Eisai; EMD Serano; Eli Lilly; GlaxoSmithKline plc; Helssin; Janssen; Onkure; Mersana; Pfizer; Quilu; Roche; Sanofi; Seattle Genetics; Takeda
Grant/Research Support: Innovata Pharmaceuticals Pty Ltd; Abbvie Inc; AstraZeneca plc; Bristol Myers Squibb Company; GlaxoSmithKline plc; Hansoh Pharmaceutical Group Co., Ltd; Inhibrx; Karyopharm Therapeutics; Lycera; MedImmune, LLC; Merck & Co, Inc; Pfizer Inc; Phosplatin Therapeutics LLC; PsiOxus Therapeutics Ltd; Rain Therapeutics Inc; Roche/Genentech Inc; Seattle Genetics; Symphogen A/S; Takeda Pharmaceutical Company Limited; Tolero Pharmaceuticals, Inc
Mark A. Socinski, MD
Executive Director
AdventHealth Cancer Institute
Orlando, FL
Faculty Disclosures:
Grant Recipient/Research Support: AstraZeneca plc; Daiichi Sankyo Company, Limited; Genentech Inc; Novartis; Spectrum Pharmaceuticals Inc; Takeda Pharmaceutical Company Limited
Promotional Speakers Bureau: AstraZeneca plc; Blueprint Medicines; Eli Lilly and Company; Genentech Inc; Jazz Pharmaceuticals; Merck & Co, Inc
Planner Disclosures:
American Academy of CME, Inc.
John JD Juchniewicz, MCIS, CHCP, FACEHP has nothing to disclose.
Beth Sandy, MSN, CRNP (Independent Reviewer)
Promotional Speakers Bureau: AstraZeneca; Jazz; Merck; Takeda
Spire Learning
Mairead Early and Allison Goldberg have nothing to disclose.
Christopher Washburn, PhD
Employee (spouse): Janssen Pharmaceuticals, Inc
Targeted Audience
Community oncologists, community nurses and nurse practitioners (NPs) and community physician assistants (PAs)
Commercial Supporter:
This activity is supported by an educational grant from Takeda Oncology.
Accreditation Statement and Credit Designation Statement:
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc., is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: American Academy of CME, Inc., designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use:
The faculty does not intend to discuss non–FDA-approved or investigational agents for the treatment of NSCLC.
Disclaimer:
The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, consult appropriate resources for any product or device mentioned in this activity, and draw conclusions only after careful consideration of all available scientific information.
Privacy Policy:
Spire Learning Privacy Policy
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm
Copyright Statement
Copyright © 2021 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and American Academy of CME, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
This activity is jointly provided by American Academy of CME and Spire Learning.
